A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)

<div>Proportion of participants achieving a ppIGA response by visit through week 48 (full analysis set). Data missing due to discontinuation of treatment are imputed with nonresponse (0). Data missing due to reasons other than discontinuation of treatment are imputed using multiple imputation. The ppIGA scale score is based on the version of the IGA modified in 2011. ppIGA response is defined as a ppIGA score of 0 (clear) or 1 (almost clear/minimal) and a ≥2-point reduction from the baseline in the ppIGA score. IGA, Investigator’s Global Assessment; ppIGA, palmoplantar Investigator’s Global Assessment.</div>

Dermatologic Therapy

fig4

Figure 4

Figure 4: A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 

Figure 4 | A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS) 